Corporate$AMGN4:01 PM ET9 wires · v9

Amgen provides pipeline updates in Q3 2026 report, including MariTide Phase 3 start and TAVNEOS withdrawal risk

By BORSA NewsroomPublished Nov 3, 2026, 4:01 PM ESTUpdated Nov 3, 2026, 4:02 PM EST

Amgen reported progress across its pipeline in its Q3 2026 financial release. MariTide Phase 3 studies have begun, while TAVNEOS faces a potential US market withdrawal.

Sentimentbullish 65

Bullish · 65 of 100

Impact70

medium · sector-wide

Confidence95%

high confidence · 9 wires

Eventconfirmed

v9 · alerted to followers

WHAT WE KNOW

MariTide Phase 3 MARITIME-T2D-3 study vs semaglutide initiated and enrolling.